Yayınlar & Eserler

Yayın Ağı
Makaleler 231
Tümü (231)
SCI-E, SSCI, AHCI (206)
SCI-E, SSCI, AHCI, ESCI (219)
ESCI (13)
Scopus (222)
TRDizin (29)
Diğer Yayınlar (2)

1. Cytoreduction in MPN-SVT: Is the Association Causal?

Demirci U., Eşkazan A. E.
Blood advances , 2026 (SCI-Expanded, Scopus)

2. Perioperative care of patients with chronic myeloid leukemia on tyrosine kinase inhibitors.

Binidris M., Žáčková D., Kaddoura R., Ghasoub R., Eşkazan A. E., Saglio G., et al.
Frontiers in oncology , cilt.16, ss.1899207, 2026 (SCI-Expanded, Scopus)

3. Impact of bone marrow fibrosis on disease characteristics and outcomes in newly diagnosed multiple myeloma patients.

Ahadzade A., Elverdi T., Kucukyurt S., Ercaliskan A., Ozkan T., Demiröz A. S., et al.
Current research in translational medicine , cilt.74, sa.3, ss.103605, 2026 (SCI-Expanded)

4. Evaluation of the frequency, risk factors, and outcomes of splanchnic vein thrombosis in myeloproliferative neoplasms: a retrospective cohort study.

Demirci U., Baysal M., Aksoy E., Mastanzade M., Bozer D. S., Gül D., et al.
Journal of thrombosis and thrombolysis , 2026 (SCI-Expanded, Scopus)

5. Revisiting the PLASMIC score and the future of ADAMTS13 prediction

Baysal M., EŞKAZAN A. E.
Blood Vessels, Thrombosis and Hemostasis , cilt.3, sa.3, 2026 (Scopus)

6. A survey on the management of chronic myeloid leukemia in chronic phase from the perspectives of both patients and physicians.

Eşkazan A. E., Yaman S., Yıldız A., Özmen D., Gürkan E., Ataş Ü., et al.
Annals of hematology , 2026 (SCI-Expanded, Scopus)

7. Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review.

Özmen D., Kürekçi D. D., Özkocaman V., Altındağ Avcı B., Bozer D. S., Kasar M., et al.
Leukemia research , cilt.166, ss.108239, 2026 (SCI-Expanded, Scopus)

8. Evaluation of hepatitis B virus screening and reactivation in patients with hematological malignancies receiving rituximab-based chemoimmunotherapy: A single-center retrospective study.

Öztürk A. E., Gioventikli A., Kanık A. B., Öztürk C., Elverdi T., Salihoğlu A., et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners , 2026 (SCI-Expanded, Scopus)

9. Evaluation of DNA methylation-based age prediction accuracy in leukemia patients using a six-CpG model trained on healthy blood.

Can K., Filoglu G., Ersoy G., Ozmen D., Eskazan A. E., Ar M. C., et al.
Forensic science, medicine, and pathology , 2026 (SCI-Expanded, Scopus)

10. Pre-procedure platelet count is not the only factor in the development of bleeding complications following lumbar puncture and central venous catheter insertion.

Eşkazan A. E.
Internal medicine journal , 2026 (SCI-Expanded, Scopus)

11. Restless legs syndrome in chronic myeloid leukemia: an overlooked condition with a significant impact on health-related quality of life.

Gürer T., Günay U. B., Kılıç B., Akkan Suzan A., Seyhan Erdoğan D., Özmen D., et al.
Annals of hematology , cilt.105, sa.4, 2026 (SCI-Expanded, Scopus)

12. Emerging Survival Predictor Model in Essential Thrombocythemia: The AAA(+) Model.

Sönmez Ö., Oyur E., Yönal Hindilerden İ., Hindilerden F., Sönmez M., Karışmaz A., et al.
American journal of hematology , 2026 (SCI-Expanded, Scopus)

13. Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.

Cebeci S., Serraç E., Elverdi T., Salihoğlu A., Ar M. C., Öngören Ş., et al.
Clinical lymphoma, myeloma & leukemia , 2026 (SCI-Expanded, Scopus)

14. Precision Anticoagulation: The Imperative Usage of DOACs for Disease-Specific Risk Stratification in MPNs and Multiple Myeloma.

Baysal M., Eşkazan A. E.
European journal of haematology , 2026 (SCI-Expanded, Scopus)

15. Frontline therapy in primary mediastinal B-cell lymphoma: when salvage outcomes redefine the meaning of intensity. Comment on: Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.

Koca O., Küçükyurt S., Eskazan A. E.
Haematologica , 2026 (SCI-Expanded, Scopus)

16. Plasma Cell Contamination in Autografts Determined by Dual Quantification Before Cryopreservation and After Thawing Predicts Transplant Outcomes in Multiple Myeloma: A Prospective, Proof-of-Concept Study

Yilmaz U., ELVERDİ T., BAYAR M., ZULFALIYEVA G., Çavuşoğlu M., Ozmen D., et al.
Cerrahpaşa Medical Journal , sa.1, ss.1-8, 2026 (TRDizin) Creative Commons License

17. Navigating biosimilar transitions in IV rituximab therapy: Efficacy and safety insights from a real-world switching study.

Erçalışkan A., Seyhan Erdoğan D., Bahar F., Belli Ç., Ortaboz D., Elverdi T., et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners , 2026 (SCI-Expanded, Scopus)

18. Determinants of Survival in Mantle Cell Lymphoma: A 20-Year Single-Center Retrospective Analysis

Muradov I., Polat A. O., ELVERDİ T., SALİHOĞLU A., AR M. C., Öngören Ş., et al.
Indian Journal of Hematology and Blood Transfusion , 2026 (SCI-Expanded, Scopus)

19. Citrullinated Histone 3 as a Marker of NETosis at Opposite Ends of Hemostasis: Evidence From Thrombosis-Prone MPN and Bleeding-Prone Hemophilia.

Olcar S., Elverdi T., Bolayırlı İ. M., Eşkazan A. E., Özmen D., Özer Çerme M. D., et al.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis , cilt.32, 2026 (SCI-Expanded, Scopus)

20. Masked polycythemia vera: diagnostic challenges and clinical implications.

Durak Z. A., Demirci Z., Eşkazan A. E.
Expert review of hematology , cilt.19, sa.1, ss.1-3, 2026 (SCI-Expanded, Scopus)

21. Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!

Özdemir Z. N., Eşkazan A. E.
Cancer , cilt.131, sa.24, 2025 (SCI-Expanded, Scopus)

22. Evaluation of contraception methods in chronic myeloid leukemia patients: A Turkish multicenter study

Çiftçiler R., Selim C., Cömert M., Zengin H., Ipek Y., Gürsoy V., et al.
Journal of Oncology Pharmacy Practice , cilt.31, sa.8, ss.1248-1255, 2025 (SCI-Expanded, Scopus)

23. Lowering the platelet count threshold to 40x10(9)/L for lumbar puncture: can this represent a generalized approach? Comment on: "40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies".

Eşkazan A. E.
Haematologica , cilt.110, ss.3176-3177, 2025 (SCI-Expanded, Scopus)

24. Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models

Koca O., Eskazan A. E.
British Journal of Haematology , cilt.207, sa.5, ss.1744-1754, 2025 (SCI-Expanded, Scopus)

25. STAMP inhibitors and their future in CML therapy: a critical analysis.

Yildiz D., Eskazan A. E.
Blood cancer journal , cilt.15, sa.1, ss.173, 2025 (SCI-Expanded, Scopus)

26. A Practical Tool for Predicting Outcomes in Essential Thrombocythemia: Triple A Risk Model and Beyond.

Sonmez O., Oyur E., Yonal-Hindilerden I., Hindilerden F., Sönmez M., Karışmaz A., et al.
Blood advances , 2025 (SCI-Expanded, Scopus)

27. Perioperative Management of Atypical Hemolytic Uremic Syndrome in a Patient on Maintenance Eculizumab Therapy: A Case Report and Review of the Literature.

Mütiş Alan A., Dinçer M. T., Kaykioğlu A., Türk B., Nuhoğlu Kantarci E., Seyahi N., et al.
Nephron , cilt.149, ss.539-544, 2025 (SCI-Expanded, Scopus)

28. Is splenectomy one of the contributory factors to pulmonary hypertension? An analysis of splenectomized hemolytic anemia and immune thrombocytopenia patients.

Birsin Z., Salihoğlu A., Tokdil K. O., Pirdal B. Z., Bilgiç S., Avcı B. K., et al.
Annals of hematology , cilt.104, ss.4447-4456, 2025 (SCI-Expanded, Scopus)

29. Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients

Küçükyurt S., Koca O., Terzi Demirsoy E., Akın S., Doğan A., Gören D., et al.
Annals of Hematology , cilt.104, sa.9, ss.4679-4690, 2025 (SCI-Expanded, Scopus)

30. Trueperella pyogenes bacteremia in a patient with nasal NK/T-cell lymphoma: A case report

Özdemir S., AYDOĞAN O., YILMAZ U., EŞKAZAN A. E., Köksal Çakırlar F.
Clinical Microbiology Newsletter , cilt.52, ss.10-13, 2025 (Scopus) Creative Commons License

31. Clinical Manifestations, Treatment Characteristics and Clinical Outcome in Patients with Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in the Real-World Setting: An Interim Analysis of the Turkish aTTP Registry.

Karakuş S., Bakanay Ş. M., Kalayoğlu Beşişik S., Eşkazan A. E., Ayyıldız O., Gürkan E., et al.
Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.42, ss.203-212, 2025 (SCI-Expanded, Scopus, TRDizin)

32. Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease.

Guliyev M., Tunc A., Yılmaz U., Kucukyurt S., Ozmen D., Elverdi T., et al.
International journal of hematology , cilt.122, ss.73-82, 2025 (SCI-Expanded, Scopus)

33. Unusual synchronous and metachronous association of hematologic neoplasms with gynecologic neoplasms: A case series and literature review.

Ozcivit Erkan I. B., Kuru O., Turker Saricoban C., Wardak M., Hamzaoglu Canbolat K., Eskazan A. E.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics , cilt.169, sa.3, ss.1025-1036, 2025 (SCI-Expanded, Scopus) Creative Commons License

34. rADAMTS13 in cTTP: a new standard of care?

EŞKAZAN A. E.
Blood , cilt.145, sa.20, ss.2243-2244, 2025 (SCI-Expanded, Scopus)

35. Comment on: "Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study" by Busque et al.

Eşkazan A. E.
Blood cancer journal , cilt.15, sa.1, ss.70, 2025 (SCI-Expanded, Scopus)

36. The validation of advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in Turkish patients with classical Hodgkin lymphoma.

Koca O., Ozyurt B., Umar A., Ozmen D., Elverdi T., Salihoglu A., et al.
Annals of hematology , cilt.104, ss.1765-1775, 2025 (SCI-Expanded, Scopus)

37. Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m².

Yılmaz U., Erdem Nurcan Ş., Özmen D., Salihoğlu A., Eşkazan A. E., Öngören Ş., et al.
Annals of transplantation , cilt.30, 2025 (SCI-Expanded, Scopus)

38. Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!

Eşkazan A. E.
Cancer , cilt.131, sa.3, 2025 (SCI-Expanded, Scopus)

39. Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology

Baysal M., Aksoy E., Bedir K. H., Özmen D., Patır P., Demirci U., et al.
Journal of Thrombosis and Thrombolysis , cilt.58, sa.2, ss.284-298, 2025 (SCI-Expanded, Scopus)

40. Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?

Çiftçiler R., Eşkazan A. E.
Future oncology (London, England) , cilt.21, ss.3589-3592, 2025 (SCI-Expanded, Scopus)

41. Complications of therapeutic plasma exchange: A retrospective, single-center study of 2505 procedures performed in 338 patients over 15 years

Vural E., Elverdi T., Salihoğlu A., Ar M. C., Öngören Ş., Başlar Z., et al.
THERAPEUTIC APHERESIS AND DIALYSIS , cilt.28, sa.6, ss.912-922, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

42. Impact Of Bone Marrow Fibrosis In Multiple Myeloma At Diagnosis and On DIsease Course

AHADZADE A., YILMAZ U., Kaya S. K., ERÇALIŞKAN A., ÖZMEN İBİŞ D., ELVERDİ T., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2024 (SCI-Expanded, Scopus)

43. Chronic myeloid leukemia in renal transplantation patients in the era of tyrosine kinase inhibitors: A case report and review of the literature

MURT A., Bayram B., YILMAZ U., SEYAHİ N., EŞKAZAN A. E.
NEPHRON , cilt.148, sa.8, ss.563-568, 2024 (SCI-Expanded, Scopus)

44. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia.

Sönmez Ö., Özgür Yurttaş N., İhtiyaroğlu İ., Çakır H. M., Atlı Z., Elverdi T., et al.
Clinical lymphoma, myeloma & leukemia , cilt.24, sa.4, ss.232-239, 2024 (SCI-Expanded, Scopus)

45. Plasma cell-directed therapy strategies in immune-mediated thrombotic thrombocytopenic purpura (iTTP).

Patır P., Önkibar N., Subari S., Eşkazan A. E.
Transfusion , cilt.64, sa.3, ss.536-545, 2024 (SCI-Expanded, Scopus)

46. Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?

Yılmaz U., Küçükyurt S., Ar M. C., Eşkazan A. E.
Oncology and therapy , cilt.12, sa.1, ss.157-161, 2024 (ESCI, Scopus)

47. Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP.

Küçükyurt S., EŞKAZAN T., Ayer M., Klllçklran Avcl B., Hatemi I., EŞKAZAN A. E.
Pleura and peritoneum , cilt.9, sa.1, ss.39-43, 2024 (ESCI) Creative Commons License

48. Erdheim-Chester disease of brain parenchyma without any systemic involvement: A case report and review of literature

Aktan Suzgun M., Everest E., Kucukyurt S., Tutuncu M., Uygunoğlu U., Eşkazan A. E., et al.
NEUROPATHOLOGY , cilt.44, sa.1, ss.59-67, 2024 (SCI-Expanded, Scopus)

49. Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

Saydan B., Ozmen D., Eşkazan A. E.
Expert Review of Hematology , cilt.17, sa.7, ss.275-277, 2024 (SCI-Expanded, Scopus)

50. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.

Davulcu E. A., Oğuz M. B., Kılıç E., Eşkazan A. E.
Expert opinion on investigational drugs , cilt.33, sa.1, ss.27-37, 2024 (SCI-Expanded, Scopus)

51. Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma

Yılmaz U., Zulfaliyeva G., Güzelli A. N., Özmen D., Elverdi T., Salihoğlu A., et al.
JOURNAL OF CHEMOTHERAPY , cilt.36, sa.5, ss.403-410, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

52. A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia

Özmen D., Alpaydın D. D., Saldoğan M. A., Eşkazan A. E.
Expert Opinion on Drug Safety , cilt.23, sa.4, ss.411-423, 2024 (SCI-Expanded, Scopus)

53. Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients Esansiyel Trombositemide CALR ve JAK2V617F Mutasyonlarının Klinik Seyir ve Hastalık Sonuçlarına Etkisi: Türk Hastalarda Geriye Dönük Çok Merkezli Çalışma

Narlı Özdemir Z., İpek Y., Patır P., Ermiş G., Çiftçiler R., Özmen D., et al.
Turkish Journal of Hematology , cilt.41, sa.1, ss.26-36, 2024 (SCI-Expanded, Scopus, TRDizin)

54. Fatal panresistant Lomentospora prolificans fungemia in a patient with aplastic anemia: First report from T(sic)rkiye

Yazgan Z., Dündar T., Barış A., Aksu Ö., EŞKAZAN A. E., Çakırlar F.
JOURNAL DE MYCOLOGIE MEDICALE , cilt.33, sa.4, 2023 (SCI-Expanded, Scopus)

55. Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient.

Nuhoğlu Kantarcı E., Tolgay E., Eşkazan A. E.
Cancer , cilt.129, ss.2610-2612, 2023 (SCI-Expanded, Scopus)

56. Sistemik lupus eritematozusda plazma değişim tedavisi: Tek merkez retrospektif kohort çalışması

Özgüler Y., Ak T., Esatoğlu S. N., Elverdi T., Eşkazan A. E., Uğurlu S., et al.
Ulusal Romatoloji Dergisi , cilt.15, sa.2, ss.89-94, 2023 (TRDizin)

57. Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial.

Genç E. E., Saraç I. S., Arslan H., Eşkazan A. E.
Oncology and therapy , sa.1, 2023 (ESCI, Scopus)

58. Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!

Eşkazan A. E.
Cancer , 2023 (SCI-Expanded, Scopus)

59. Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis

Küçükyurt S., Kelezoğlu A., Elverdi T., Özmen D., Ar M. C., Eşkazan A. E.
Hematology, Transfusion and Cell Therapy , cilt.45, sa.2, ss.275-277, 2023 (ESCI, Scopus)

60. SPINK2 elevation in acute myeloid leukemia Elevación de SPINK2 en leucemia mieloide aguda

Gezer S., EMRENCE Z., ELVERDİ T., AR M. C., Salman Yaylaz B., PAÇAL F., et al.
Advances in Laboratory Medicine , cilt.4, sa.1, ss.98-104, 2023 (ESCI, Scopus) Creative Commons License

61. Editorial: Advances in the treatment of chronic myeloid leukemia

Eşkazan A. E., Kok C. H., Yeung D., Dalal J., Tiribelli M.
FRONTIERS IN ONCOLOGY , cilt.13, ss.1-2, 2023 (SCI-Expanded, Scopus)

62. Breaking the mold: asciminib as a standard of care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting.

Yılmaz R., Eşkazan A. E.
Future oncology (London, England) , cilt.19, ss.545-547, 2023 (SCI-Expanded, Scopus)

63. Upregulation of SPINK2 in acute myeloid leukemia

Gezer S., Emrence Z., Elverdi T., Ar M. C., Yaylaz B. S., Pacal F., et al.
ADVANCES IN LABORATORY MEDICINE-AVANCES EN MEDICINA DE LABORATORIO , cilt.4, sa.1, ss.92-97, 2023 (ESCI, Scopus) Creative Commons License

64. Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!

Eşkazan A. E.
Cancer , cilt.129, ss.643-644, 2023 (SCI-Expanded, Scopus)

65. Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib-Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib

ILTAR U., SALİM O., Atas U., Vural E., Alhan F. N., YÜCEL O. K., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , sa.4, ss.191-197, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

66. Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults.

Mersin S., Gülük F., Gülcan E., Eşkazan A. E.
Expert opinion on pharmacotherapy , cilt.24, ss.1703-1713, 2023 (SCI-Expanded, Scopus)

67. A cross-sectional study on restless legs syndrome (RLS) in polycythemia vera (PV): is iron deficiency the only culprit?

Seyhan Erdoğan D., Benbir Şenel G., Gündüz A., Uçar B. P., Elverdi T., Salihoğlu A., et al.
Neurological Research , cilt.45, sa.12, ss.1144-1151, 2023 (SCI-Expanded, Scopus)

68. Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review.

Baysal M., Bayrak M., Eşkazan A. E.
Expert review of hematology , cilt.16, ss.131-140, 2023 (SCI-Expanded, Scopus)

69. Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis.

Ipek Y., Kilic B., Gunay U. B., Eskazan A. E.
Expert opinion on investigational drugs , cilt.32, ss.931-940, 2023 (SCI-Expanded, Scopus)

70. ATRA+ATO combination in APL – A commentary on “evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades” by Teng-Fei et al.

Ortaboz D., Çetin M. S., Cömert B., Eşkazan A. E.
TRANSLATIONAL ONCOLOGY , cilt.0, sa.0, ss.1-3, 2023 (SCI-Expanded, Scopus)

71. A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?

Çiftçiler R., Akın M. G., Erat Z., Eşkazan A. E.
Clinical lymphoma, myeloma & leukemia , cilt.23, ss.8-14, 2023 (SCI-Expanded, Scopus)

72. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities.

Narlı Özdemir Z., Kılıçaslan N. A., Yılmaz M., Eşkazan A. E.
International journal of hematology , cilt.117, ss.3-15, 2023 (SCI-Expanded, Scopus)

73. Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic ⁎

Küçükyurt S., Şahin K., Yılmaz U., Erçalışkan A., Özkan Tekin T., Ortaboz D., et al.
Current Problems in Cancer , cilt.46, sa.6, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

74. ANCA ile ilişkili vaskülitte plazma değişim tedavisi: Tek merkez retrospektif kohort çalışması

Özgüler Y., Ak T., Esatoğlu S. N., Elverdi T., Eşkazan A. E., Uğurlu S., et al.
Ulusal Romatoloji Dergisi , cilt.14, sa.3, ss.131-136, 2022 (Scopus, TRDizin)

75. Olverembatinib in chronic myeloid leukemia.

Öziskender R., Eşkazan A. E.
Drugs of today (Barcelona, Spain : 1998) , cilt.58, sa.11, ss.531-538, 2022 (SCI-Expanded, Scopus)

76. Kikuchi Fujimoto disease as the presenting component of VEXAS syndrome: a case report of a probable association

Yılmaz U., Güner S., Eşkazan T., Demiröz A. S., Kurtuluş G., Bahar F., et al.
CLINICAL RHEUMATOLOGY , cilt.41, sa.11, ss.3589-3592, 2022 (SCI-Expanded, Scopus)

77. Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase.

Yılmaz U., Küçükyurt S., Tunç S., Eşkazan A. E.
Frontiers in oncology , cilt.12, sa.1, ss.994101, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

78. Treatment of Mantle-Cell Lymphoma.

Eşkazan A. E.
The New England journal of medicine , cilt.387, sa.12, ss.1147-1148, 2022 (SCI-Expanded, Scopus)

79. A new dawn for upfront autologous SCT in NK/T-cell lymphomas: One more step forward in reasoning

Elverdi T., Hıyamlı M. F., Şahin B., Eşkazan A. E.
INTERNATIONAL JOURNAL OF CANCER , cilt.151, sa.5, ss.661-664, 2022 (SCI-Expanded, Scopus)

80. Cytogenetic profile of adult AML patients in Turkey: a single center study with comprehensive comparison with literature

Cirakoglu A., Kuru R. D., Yilmaz S., Deviren A., Ongoren S., Yalniz F. F., et al.
AFRICAN HEALTH SCIENCES , sa.3, ss.183-191, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

81. Recent Advances in the Therapeutic Armamentarium of Acute Myeloid Leukemia: A Focus on the 63rd American Society of Hematology Annual Meeting Abstracts.

Bayraktar E. A., Küçükyurt S., Eşkazan A. E.
Current pharmaceutical design , cilt.28, ss.2687-2689, 2022 (SCI-Expanded, Scopus)

82. Rare and Aggressive Disease: Challenge

Sönmez Ö., Küçükyurt S., Önenerk Men A. M., Demiröz A. S., Eşkazan A. E.
AMERICAN JOURNAL OF DERMATOPATHOLOGY , cilt.44, sa.8, 2022 (SCI-Expanded, Scopus)

83. A Rare and Aggressive Disease: Answer

Sönmez Ö., Küçükyurt S., Önenerk Men A. M., Demiröz A. S., Eşkazan A. E.
AMERICAN JOURNAL OF DERMATOPATHOLOGY , cilt.44, sa.8, ss.613-614, 2022 (SCI-Expanded, Scopus)

84. Voxelotor: A new kid on the block in the treatment of sickle cell disease.

Çanak B., Eşkazan A. E.
British journal of clinical pharmacology , cilt.88, ss.2564-2565, 2022 (SCI-Expanded, Scopus)

85. The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Saydam G., Ali R., Demir A. M., Eskazan A. E., Guvenc B., Haznedaroglu I. C., et al.
International journal of hematologic oncology , cilt.11, sa.1, 2022 (Hakemli Dergi)

86. Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review.

Yılmaz U., Bulan B., Belli Ç., Eşkazan A. E.
Expert review of hematology , cilt.15, ss.423-429, 2022 (SCI-Expanded)

87. Is it possible to predict the pCR with CBC? A commentary on "correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer" by Meng et al.

Tanrıkulu Şimşek E., Bayram B., Yıldırım A., Eşkazan A. E.
Translational oncology , cilt.20, ss.101403, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

88. Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.

Hatırnaz Ng Ö., Eşkazan A. E.
Translational oncology , cilt.19, ss.101394, 2022 (SCI-Expanded, Scopus)

89. Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.

Nuhoğlu Kantarcı E., Eşkazan A. E.
Leukemia research , cilt.114, ss.106808, 2022 (SCI-Expanded, Scopus)

90. Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting.

Eskazan A. E., Ali R., Alnıgeniş E., Ayyıldız O., Haznedaroğlu İ., Kırkızlar O., et al.
Expert review of hematology , cilt.15, ss.97-106, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

91. F-18-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behcet's Disease

İnce B., Kibar A., Asa S., Uslu Beşli R. L., Sağer M. S., Eşkazan A. E., et al.
MOLECULAR IMAGING AND RADIONUCLIDE THERAPY , cilt.31, sa.1, ss.57-59, 2022 (ESCI, TRDizin) Creative Commons License

92. Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged >= 50 Years: A Single-Center Experience Over Two Decades

Çokgezer S., Elverdi T., Salihoğlu A., Ar M. C., Öngören Ş., Başlar Z., et al.
CANCER MANAGEMENT AND RESEARCH , cilt.14, ss.1911-1921, 2022 (SCI-Expanded, Scopus)

93. Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience Biyobenzer Rituksimab (Redditux) ile CHOP Kemoterapisinin Yeni Tanı Diffüz Büyük B-Hücreli Lenfoma Hastalarında Kullanımı: Gerçek Yaşam Tek Merkez Deneyimi

Özbalak M., Güzel Mastanzade M., Özlük Ö., Tiryaki T. O., Erdem S., Özbalak E. P., et al.
Turkish Journal of Hematology , cilt.39, sa.4, ss.254-261, 2022 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

94. Successful Management of Ibrutinib-induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia.

Erçalışkan A., Avcı F. Z., Eşkazan A. E.
Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.39, ss.275-276, 2022 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

95. Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame?

Kılıçaslan N. A., Börekçi Ş., Özdemir G. N., Sayitoğlu M., Eşkazan A. E.
Expert review of respiratory medicine , cilt.16, ss.849-852, 2022 (SCI-Expanded, Scopus)

96. Genetic Features and TP53 Mutations in Chronic Lymphocytic Leukemia

Özünal I. E., , Elverdi T., Salihoğlu A., Eşkazan A. E., Ar M. C., et al.
Cerrahpasa Medical Journal , cilt.45, sa.3, 2021 (TRDizin)

97. The Impact of EUTOS Long-Term Survival (ELTS) Score on Predicting Progression and Survival Among Turkish Patients with Chronic Myeloid Leukemia

Bektaş M., Elverdi T., Salihoğlu A., Ar M. C., Öngören Ş., Başlar Z., et al.
Blood , cilt.138, sa.Supplement 1, 2021 (SCI-Expanded, Scopus)

98. Treatment Responses, Toxicity and Survival in Patients with Classical Hodgkin Lymphoma Aged 50 Years and Older: A Single-Center Experience over 2 Decades

Çokgezer S., Elverdi T., Salihoğlu A., Ar M. C., Öngören Ş., Başlar Z., et al.
Blood , cilt.138, sa.Supplement 1, 2021 (SCI-Expanded, Scopus)

99. The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience

Kucukyurt S., Şahin K., Yılmaz U., Erçalışkan A., Özkan Tekin T., Ortaboz D., et al.
Blood , cilt.138, sa.Supplement 1, 2021 (SCI-Expanded, Scopus)

100. Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?

Elverdi T., Özer Çerme M. D., Aydın T., Eşkazan A. E.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY , cilt.14, sa.10, ss.1183-1188, 2021 (SCI-Expanded, Scopus) Creative Commons License

101. Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al.

Aydın T., Elverdi T., Özer Çerme M. D., Eşkazan A. E.
Journal of thrombosis and haemostasis : JTH , cilt.19, sa.10, ss.2644-2646, 2021 (SCI-Expanded, Scopus)

102. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs.

Erçalışkan A., Seyhan Erdoğan D., Eşkazan A. E.
Blood advances , cilt.5, ss.3344-3353, 2021 (SCI-Expanded, Scopus)

103. Asciminib as a new option in the treatment of chronic myeloid leukemia.

İbiş B., Tiribelli M., Eşkazan A. E.
Future oncology (London, England) , cilt.17, ss.5003-5005, 2021 (SCI-Expanded, Scopus)

104. Tocilizumab in COVID-19: The Cerrahpas , a-PREDICT score

Eşkazan A. E., Balkan İ. İ., Demirbaş K. C., Ar M. C., Karaali R., Sekibağ Y., et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY , cilt.27, sa.9, ss.1329-1335, 2021 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

105. Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience

Eşkazan A. E., Özmen D., Öztaş M., Bektaş F., Bayraktar E. A., Sadri S., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.21, sa.8, ss.549-557, 2021 (SCI-Expanded, Scopus)

106. New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on "C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases".

Küçükyurt S., Bahar F., Eşkazan A. E.
Translational oncology , cilt.14, ss.101098, 2021 (SCI-Expanded, Scopus)

107. A clinical appraisal of chronic myeloid leukaemia (CML)-related death and CML-specific death-Are they synonymous?

Eşkazan A. E.
International journal of clinical practice , cilt.75, 2021 (SCI-Expanded, Scopus)

108. What is the best treatment approach for sporadic late-onset nemaline myopathy associated with "monoclonal gammopathy of neurological significance"?

Eşkazan A. E., Gündüz A.
International journal of cancer , cilt.148, sa.11, ss.2638-2639, 2021 (SCI-Expanded, Scopus)

109. Candida esophagitis incidentally detected by 18F-FDG PET/CT in a patient with CNS lymphoma.

Bayar M., Özgür Yurttaş N., Bilgiç S., Karakuş K., Önal U., Sönmezoğlu K., et al.
Clinical case reports , cilt.9, 2021 (ESCI, Scopus) Creative Commons License

110. Asciminib in chronic myeloid leukemia: many questions still remain to be answered.

Eşkazan A. E.
Blood cancer journal , cilt.11, ss.81, 2021 (SCI-Expanded, Scopus) Creative Commons License

111. Bosutinib - related pleural effusion in patients with chronic myeloid leukemia.

Yüzbaşıoğlu M. B., Eşkazan A. E.
Expert opinion on drug safety , cilt.20, ss.379-381, 2021 (SCI-Expanded, Scopus)

112. KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY

Ozbalak M., Ozunal I. E., Berk S., ELVERDİ T., SALİHOĞLU A., EŞKAZAN A. E., et al.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , cilt.84, sa.2, ss.227-236, 2021 (ESCI, TRDizin)

113. COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey

Yılmaz U., Pekmezci A., Gül Y., Eşkazan A. E.
Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.38, ss.79-81, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

114. Giant Cell Arteritis with Concomitant Chronic Myelomonocytic Leukemia

Öztaş M., Muradov I., Erçalışkan A., Demiröz A. S., Batur Ş., Eşkazan A. E., et al.
TURKISH JOURNAL OF HEMATOLOGY , cilt.38, sa.3, ss.226-227, 2021 (SCI-Expanded, Scopus, TRDizin)

115. COVID-19 presenting with immune thrombocytopenia: A case report and review of the literature

Murt A., Eskazan A. E., Yılmaz U., Ozkan T., Ar M. C.
JOURNAL OF MEDICAL VIROLOGY , cilt.93, sa.1, ss.43-45, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

116. Platelet count threshold for lumbar puncture: Does one size really fit all?

Eşkazan A. E.
Transfusion , cilt.61, ss.329, 2021 (SCI-Expanded, Scopus)

117. The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naive patients with chronic lymphocytic leukemia

Esatoğlu S. N., Keskin D., Eşkazan A. E., Elverdi T., Salihoğlu A., Ar M. C., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.51, sa.1, ss.348-354, 2021 (SCI-Expanded, Scopus, TRDizin)

118. Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Malik S., Hassan S., Eşkazan A. E.
Expert review of hematology , cilt.14, sa.11, ss.975-978, 2021 (SCI-Expanded, Scopus)

119. Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation

Sengul S., Yılmaz U., Bedir S., Ozgur Y., Oruc K., Durak S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.8, ss.2042-2046, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

120. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country

Murt A., Elverdi T., Eskazan A. E., Salihoglu A., Ar M. C., Ongoren S., et al.
Annals of Hematology , cilt.99, sa.11, ss.2671-2677, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

121. Copy-number variations in adult patients with chronic immune thrombocytopenia

Yucesan E., Hatirnaz N., Yalniz F., Yilmaz H., Salihoglu A., Sudutan T., et al.
EXPERT REVIEW OF HEMATOLOGY , cilt.13, sa.11, ss.1277-1287, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

122. Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

Kucukyurt S., Yagiz Ozogul Y., Ercaliskan A., Kabasakal L., Eskazan A. E.
CANCER REPORTS , cilt.3, sa.5, 2020 (ESCI, Scopus)

123. Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

Yilmaz U., Eskazan A. E.
Expert review of hematology , cilt.13, ss.1035-1038, 2020 (SCI-Expanded, Scopus)

124. Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.

Eşkazan A. E.
British journal of clinical pharmacology , cilt.86, ss.1790-1792, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

125. Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia: What is the Best Strategy?

Kucukyurt S., Elverdi T., Eskazan A. E.
Biology of Blood and Marrow Transplantation , cilt.26, sa.9, 2020 (SCI-Expanded, Scopus)

126. The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience.

Sevinc M., Karabulut A., Eskazan A. E., Catal T., Ozbek U., Soysal T.
Laboratory medicine , cilt.51, ss.259-264, 2020 (SCI-Expanded, Scopus)

127. Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.

Corbali M., Eskazan A. E.
Future oncology (London, England) , cilt.16, 2020 (SCI-Expanded, Scopus)

128. Novel therapeutic approaches in chronic myeloid leukemia.

Özgür Y., Eşkazan A. E.
Leukemia research , cilt.91, ss.106337, 2020 (SCI-Expanded, Scopus)

129. Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?

Eşkazan A. E.
Leukemia , 2020 (SCI-Expanded, Scopus)

130. Assessment and monitoring of patients with immune-mediated thrombotic thrombocytopenic purpura (ITTP): Strategies to improve outcomes

Kucukyurt S., Eskazan A. E.
Journal of Blood Medicine , cilt.11, ss.319-326, 2020 (ESCI, Scopus)

131. Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?

Yilmaz U., EŞKAZAN A. E.
CANCER , cilt.126, sa.2, ss.256-259, 2020 (SCI-Expanded, Scopus)

132. Bosutinib - an effective and safe treatment option in the management of chronic myeloid leukemia.

Ercaliskan A., Eskazan A. E.
Future oncology (London, England) , cilt.16, ss.4425-4428, 2020 (SCI-Expanded, Scopus)

133. Age-Related Co-Expression of BCOR and BCORL1 mRNA in Acute Myeloid Leukemia

Coskun F., Percin-Pacal F., Emrence Z., Ar M. C., Abaci N., Unuvar A., et al.
CLINICAL LABORATORY , cilt.66, sa.8, ss.1485-1493, 2020 (SCI-Expanded, Scopus)

134. New drugs approved for acute myeloid leukaemia in 2018.

Küçükyurt S., Eskazan A. E.
British journal of clinical pharmacology , cilt.85, ss.2689-2693, 2019 (SCI-Expanded, Scopus) Creative Commons License

135. Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia

Tiribelli M., Eşkazan A. E.
ONCOLOGY AND THERAPY , cilt.7, ss.95-100, 2019 (ESCI, Scopus) Creative Commons License

136. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?

EŞKAZAN A. E.
British journal of clinical pharmacology , cilt.85, sa.10, ss.2241-2243, 2019 (SCI-Expanded, Scopus)

137. Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma

Aydin Y., Salihoglu A., Uygunoglu U., Keskin D., YURTTAS N. O., Ozmen D., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.19, sa.10, 2019 (SCI-Expanded, Scopus)

138. Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?

Eskazan A. E.
Leukemia & lymphoma , cilt.60, ss.2094-2095, 2019 (SCI-Expanded, Scopus)

139. The tolerability issue of generic imatinib in patients with chronic myeloid leukemia <i>(Comment on Adi J. Klil-Drori et al., Haematologica 2019;104(7):e293)</i>.

Eskazan A. E., Soysal T.
Haematologica , cilt.104, 2019 (SCI-Expanded, Scopus) Creative Commons License

140. An alternative way - tyrosine kinase inhibitor (TKI) de-escalation - to discontinue TKIs in order to achieve treatment-free remission.

Kunbaz A., Eskazan A. E.
Expert review of hematology , cilt.12, ss.477-480, 2019 (SCI-Expanded, Scopus) Creative Commons License

141. The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations

Soysal T., Eskazan A. E., Serin I., Sadri S., Keskin D., YURTTAS N. O., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.19, sa.7, 2019 (SCI-Expanded, Scopus)

142. Tyrosine Kinase Inhibitor-Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?

Yurttas N., Eskazan A. E.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis , cilt.25, 2019 (SCI-Expanded, Scopus) Creative Commons License

143. Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword.

Eskazan A. E.
Acta oncologica (Stockholm, Sweden) , cilt.58, ss.123-124, 2019 (SCI-Expanded, Scopus) Creative Commons License

144. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura

Elverdi T., Eskazan A. E.
DRUG DESIGN DEVELOPMENT AND THERAPY , cilt.13, ss.1251-1258, 2019 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

145. Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

Erbilgin Y., Eskazan A. E., Hatirnaz N., Salihoglu A., Elverdı T., Firtina S., et al.
LEUKEMIA & LYMPHOMA , cilt.60, sa.1, ss.200-207, 2019 (SCI-Expanded)

146. Coexistence of Hermansky-Pudlak syndrome and JAK2<sup>V617F</sup>-positive essential thrombocythemia.

Eskazan T., Erturkuner S., Isildar B., Eskazan A. E., Ar M. C., Atay K., et al.
Ultrastructural pathology , cilt.43, ss.94-98, 2019 (SCI-Expanded, Scopus)

147. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

Eskazan A. E., Tırıbellı M.
Leukemia research , cilt.74, ss.55-56, 2018 (SCI-Expanded, Scopus)

148. Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?

Eskazan A. E.
CANCER , cilt.124, sa.21, ss.4260-4261, 2018 (SCI-Expanded, Scopus) Creative Commons License

149. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.

Ercaliskan A., Eskazan A. E.
Cancer , cilt.124, sa.19, ss.3806-3818, 2018 (SCI-Expanded, Scopus) Creative Commons License

150. Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

Eskazan A. E.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY , cilt.84, sa.8, ss.1635-1638, 2018 (SCI-Expanded, Scopus) Creative Commons License

151. The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis.

Eskazan A. E.
Journal of medical economics , cilt.21, ss.709-711, 2018 (SCI-Expanded, Scopus) Creative Commons License

152. Dasatinib-induced pulmonary arterial hypertension

Yurttas N. O., Eskazan A. E.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY , cilt.84, sa.5, ss.835-845, 2018 (SCI-Expanded, Scopus) Creative Commons License

153. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature

Ongoren S., Eskazan A., Suzan V., Savci S., Erdogan O., Berk S., et al.
Hematology , cilt.23, sa.4, ss.212-220, 2018 (SCI-Expanded, Scopus) Creative Commons License

154. Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib

Eskazan A. E.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.23, sa.2, ss.400-401, 2018 (SCI-Expanded, Scopus)

155. Comment and response to: the significance of early warning in chronic myeloid leukemia.

Eskazan A. E., Ar M. C., Soysal T.
Expert review of hematology , cilt.11, ss.267-268, 2018 (SCI-Expanded, Scopus) Creative Commons License

156. Vincristine as an adjunct to therapeutic plasma exchange for thrombotic thrombocytopenic purpura: A single-institution experience

Ongoren S., Salihoglu A., Apaydin T., Sadri S., Eskazan A. E., Ar M. C., et al.
Balkan Medical Journal , cilt.35, sa.6, ss.417-421, 2018 (SCI-Expanded, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma

157. Cytopenia in adult brucellosis patients.

Kaya S., Elaldı N., Devecı O., Eskazan A. E., Bekcıbası M., Hosoglu S.
The Indian journal of medical research , cilt.147, ss.73-80, 2018 (SCI-Expanded, Scopus)

158. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

Eskazan A. E., Sadri S., Keskin D., Ayer M., KANTARCIOGLU B., DEMIREL N., et al.
Clinical Lymphoma, Myeloma and Leukemia , cilt.17, sa.12, ss.804-811, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

159. Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.

Ongoren S., Eşkazan A. E., Berk S., Elverdı T., Salıhoglu A., Ar M. C., et al.
Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.34, ss.291-299, 2017 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

160. Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia

Eskazan A. E.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.17, sa.12, 2017 (SCI-Expanded, Scopus)

161. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia

Eskazan A. E.
NEW ENGLAND JOURNAL OF MEDICINE , cilt.377, sa.19, ss.1901, 2017 (SCI-Expanded, Scopus)

162. Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Eskazan A. E.
Leukemia &amp; lymphoma , cilt.58, ss.2516-2517, 2017 (SCI-Expanded, Scopus)

163. Retrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience

Öngören Ş., Eşkazan A. E., Berk S., Elverdi T., Salihoğlu A., Ar M. C., et al.
Turkish Journal of Hematology , 2017 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

164. Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

Eskazan A. E., Keskin D.
Therapeutic advances in hematology , cilt.8, ss.237-243, 2017 (SCI-Expanded) Creative Commons License

165. Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.

Yalniz F. F., Akkoc N., Salihoglu A., Ar M. C., Ongoren S., Eskazan A. E., et al.
Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.34, sa.3, ss.233-238, 2017 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

166. Do all patients with chronic myeloid leukemia need to receive interferon during pregnancy?

Eskazan A. E.
Leukemia &amp; lymphoma , cilt.58, ss.2019-2020, 2017 (SCI-Expanded, Scopus)

167. Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase.

Eskazan A. E.
Expert opinion on pharmacotherapy , cilt.18, ss.325-326, 2017 (SCI-Expanded, Scopus) Creative Commons License

168. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Eskazan A. E., Ozmen D.
EXPERT REVIEW OF HEMATOLOGY , cilt.10, sa.7, ss.583-586, 2017 (SCI-Expanded, Scopus) Creative Commons License

169. Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting

Eskazan A. E.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , cilt.72, sa.12, ss.1537-1538, 2016 (SCI-Expanded, Scopus)

170. Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura

Eskazan A. E.
ANNALS OF HEMATOLOGY , cilt.95, sa.11, ss.1751-1756, 2016 (SCI-Expanded, Scopus)

171. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.

Keskin D., Sadri S., Eskazan A. E.
Drug design, development and therapy , cilt.10, ss.3355-3361, 2016 (SCI-Expanded, Scopus) Creative Commons License

172. Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?

Eskazan A. E., Ar M. C., Soysal T.
Expert review of hematology , cilt.9, ss.919-21, 2016 (SCI-Expanded, Scopus) Creative Commons License

173. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.

Simsek E. T., Eskazan A. E., Cengiz M., Ar M. C., Ekizoglu S., Salihoglu A., et al.
Journal of clinical pathology , cilt.69, sa.9, ss.810-6, 2016 (SCI-Expanded, Scopus)

174. Treatment of patients with immune thrombocytopenia admitted to the emergency room.

Bavunoğlu I., Eşkazan A. E., Ar M. C., Cengiz M., Yavuzer S., Salihoğlu A., et al.
International journal of hematology , cilt.104, ss.216-22, 2016 (SCI-Expanded, Scopus)

175. Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha

Salihoglu A., Elverdi T., Eskazan A. E., Eyice D., Bavunoglu I., Ar M. C., et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , cilt.32, 2016 (SCI-Expanded, Scopus) Creative Commons License

176. Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.

Öztürk E., Özbalak M. M., Berk S., Erdoğan I., Avşar E., Dolgun A., et al.
Leukemia &amp; lymphoma , cilt.57, ss.1211-4, 2016 (SCI-Expanded, Scopus)

177. Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpasa experience

Eskazan A. E., Soysal T.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.22, sa.2, ss.382-384, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

178. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases

Eskazan A. E.
CLINICAL THERAPEUTICS , cilt.38, sa.3, ss.680-681, 2016 (SCI-Expanded, Scopus) Creative Commons License

179. Pleural tuberculosis in a patient with untreated type 1 Gaucher disease

Dulgar O., Eskazan A. E., Ersen E., Demiroz A. S., Turna A., Oz B., et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY , cilt.22, ss.53-57, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

180. The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients

Yemışen M., Balkan İ. İ., Salıhoğlu A., Eşkazan A. E., Mete B., Ar M. C., et al.
TURKISH JOURNAL OF HEMATOLOGY , cilt.33, sa.3, ss.216-222, 2016 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

181. Posttransplant Secondary Neoplasms: A Single Center Experience

Berk S., Keskin D., Ozgur Yurttas N., Sadri S., Erdogan I., Yalniz F., et al.
Blood , cilt.126, sa.23, 2015 (SCI-Expanded, Scopus)

182. Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia

Tanrikulu Simsek E., Eskazan A. E., Cengiz M., Ar M. C., Ekizoglu S., Salihoglu A., et al.
Blood , cilt.126, sa.23, 2015 (SCI-Expanded, Scopus)

183. Haemophilic Arthropathy Is a Risk Factor for Reduced Bone Mineral Density and Vitamin D Deficiency

Ar M. C., Sahin S., Sadri S., Erdogan I., Salihoglu A., Elverdi T., et al.
Blood , cilt.126, sa.23, 2015 (SCI-Expanded, Scopus)

184. Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?

Eskazan A. E., Erdogan I., Berk S., Yalniz F. F., Elverdi T., Salihoglu A., et al.
LEUKEMIA & LYMPHOMA , cilt.56, sa.10, ss.2995-2996, 2015 (SCI-Expanded, Scopus)

185. Second primary malignancies in chronic myeloid leukemia patients.

Caliskan T., Eskazan A. E.
Journal of cancer research and therapeutics , cilt.11, ss.1042, 2015 (SCI-Expanded, Scopus)

186. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode

Demirel A., Tabak F., Ar M. C., Mete B., Ongoren S., Yemisen M., et al.
TURKISH JOURNAL OF HEMATOLOGY , cilt.32, sa.3, ss.243-250, 2015 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

187. Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?

ÇETİN G., Cikrikcioglu M. A., Ozkan T., KARATOPRAK C., Ar M. C., Eskazan A. E., et al.
Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.32, sa.3, ss.213-9, 2015 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

188. Treatment and outcome of primary and secondary thrombotic microangiopathies

Eskazan A. E., Salihoglu A.
American Journal of Nephrology , cilt.41, ss.427-428, 2015 (SCI-Expanded, Scopus)

189. The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment

Eskazan A. E., Soysal T.
LEUKEMIA & LYMPHOMA , cilt.56, sa.5, ss.1554-1555, 2015 (SCI-Expanded)

190. The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?

Eskazan A. E., Ar M. C., Soysal T.
LEUKEMIA & LYMPHOMA , cilt.56, sa.4, ss.1182-1183, 2015 (SCI-Expanded, Scopus)

191. Radotinib in the treatment of chronic phase chronic myeloid leukemia patients

Eskazan A. E., Soysal T.
HAEMATOLOGICA , cilt.100, sa.1, 2015 (SCI-Expanded, Scopus) Creative Commons License

192. Postoperative thrombotic thrombocytopenic purpura

Eskazan A. E., Buyuktas D., Soysal T.
SURGERY TODAY , cilt.45, sa.1, ss.8-16, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

193. The Prognostic Value of Serum APRIL Levels in Patients with Chronic Lymphocytic Leukemia

Esatoglu S. N., Keskin D., Kutnu M., Elverdi T., Salihoglu A., Eskazan A. E., et al.
Blood , cilt.124, sa.21, 2014 (SCI-Expanded, Scopus)

194. Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy

Eskazan A. E., Hatemi I., Aydin S. O., Ar M. C., Soysal T.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.25, ss.233, 2014 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

195. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence

Soysal T., Eskazan A. E., Ar M. C.
EXPERT REVIEW OF HEMATOLOGY , cilt.7, sa.6, ss.697-699, 2014 (SCI-Expanded, Scopus)

196. Spondylodiscitis: evaluation of patients in a tertiary hospital

KAYA S., ERCAN S., KAYA S., AKTAS U., KAMASAK K., OZALP H., et al.
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES , cilt.8, sa.10, ss.1272-1276, 2014 (SCI-Expanded, Scopus) Creative Commons License

197. Bone-specific alkaline phosphatase levels among patients with multiple myeloma receiving various therapy options Farkli Tedavi Rejimleri Alan Multipl Myelom Hastalarinda Kemik Spesifik Alkalen Fosfataz Düzeyleri

ÇETİN G., Eskazan A. E., Ar M. C., Aydin S. O., Ferhanoglu B., Soysal T., et al.
Turkish Journal of Hematology , cilt.31, sa.4, ss.374-380, 2014 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

198. 466Skin lesions in febrile neutropenic patients

Yemisen M., Vatan A., Balkan I., Salihoglu A., Elverdi T., Eskazan E., et al.
Open Forum Infectious Diseases , cilt.1, sa.suppl_1, 2014 (Scopus) Creative Commons License

199. Two Cases of Autoimmune Hemolytic Anemia Secondary to Brucellosis: A Review of Hemolytic Disorders in Patients with Brucellosis

Eskazan A. E., Dal M. S., KAYA S., Dal T., Ayyildiz O., Soysal T.
INTERNAL MEDICINE , cilt.53, sa.11, ss.1153-1158, 2014 (SCI-Expanded, Scopus) Creative Commons License

200. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion

Eskazan A. E., Eyice D., Kurt E. A., Elverdi T., Yalniz F. F., Salihoglu A., et al.
Leukemia Research , cilt.38, sa.7, ss.781-787, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

201. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia

Eskazan A. E., Elverdi T., Yalniz F. F., Salihoglu A., Ar M. C., Aydin S. O., et al.
Leukemia and Lymphoma , cilt.55, sa.12, ss.2935-2937, 2014 (SCI-Expanded, Scopus)

202. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

Eskazan A. E., Ayer M., Kantarcioglu B., Arica D., Demirel N., Aydin D., et al.
British Journal of Haematology , cilt.167, sa.1, ss.139-141, 2014 (SCI-Expanded, Scopus)

203. Bone marrow transplantation for Behçet's disease: A case report and systematic review of the literature

Soysal T., Salihoglu A., Esatoglu S. N., Gulturk E., Eskazan A. E., Hatemi G., et al.
Rheumatology (United Kingdom) , cilt.53, sa.6, ss.1136-1141, 2014 (SCI-Expanded, Scopus) Creative Commons License

204. Interstitial pneumonitis in a patient with chronic myeloid leukemia.

Eşkazan A. E., Salihoğlu A., Erturan S. S., Soysal T.
Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.30, ss.435-6, 2013 (SCI-Expanded, Scopus, TRDizin)

205. Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients.

ŞAHİN F., SAYDAM G., Comert M., Uz B., Yavuz A. S., Turan E., et al.
Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.30, sa.4, ss.351-8, 2013 (SCI-Expanded, Scopus, TRDizin)

206. Successful Management of Chronic Refractory Immune Thrombocytopenia with Laparoscopic Splenectomy in a Patient with Acute Promyelocytic Leukemia

Eskazan A. E., Salihoglu A., Gulturk E., Aydin S. O., Tuzuner N., Aydin Y.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , cilt.29, ss.173-177, 2013 (SCI-Expanded, Scopus)

207. Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study.

Ozbalak M., Ar M., Tuzuner N., Salihoglu A., Eskazan A. E., Ongoren A., et al.
ISRN hematology , cilt.2013, ss.908191, 2013 (Hakemli Dergi)

208. Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature

YILMAZ M., Eskazan A. E., UNSAL A., TANINMIS H., KARA E., CETINER M., et al.
TRANSFUSION , cilt.53, sa.7, ss.1586-1593, 2013 (SCI-Expanded, Scopus)

209. Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

Eskazan A. E., Soysal T.
TURKISH JOURNAL OF HEMATOLOGY , cilt.30, sa.2, ss.211-213, 2013 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

210. Brucellar pericarditis: a report of four cases and review of the literature

KAYA S., Eskazan A. E., ELALDI N.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , cilt.17, sa.6, 2013 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

211. Simultaneous detection of B-cell chronic lymphocytic leukemia and colon adenocarcinoma in the same mesenteric lymph node Ayni mezenterik lenf bezinde B-hücreli kronik lenfositik lösemi ve kolon adenokanserinin eş zamanli saptanmasi

Eşkazan A. E., Berk S., Özden F., Erdamar S., Tüzüner N., Soysal T.
Turkish Journal of Hematology , cilt.30, ss.98-99, 2013 (SCI-Expanded, Scopus, TRDizin)

212. Acute Acalculous Cholecystitis due to Viral Hepatitis A.

Kaya S., Eskazan A. E., Ay N., Baysal B., Bahadir M., Onur A., et al.
Case reports in infectious diseases , cilt.2013, ss.407182, 2013 (ESCI) Creative Commons License Sürdürülebilir Kalkınma

213. Breast schwannoma in a patient with diffuse large B-cell lymphoma: a case report.

Salihoglu A., Esatoglu S. N., Eskazan A. E., Halac M., Aydin S.
Journal of medical case reports , cilt.6, ss.423, 2012 (Scopus) Creative Commons License

214. Intracranial extramedullary hematopoiesis in patients with thalassemia: a case report and review of the literature

Eskazan A. E., Ar M. C., Baslar Z.
TRANSFUSION , cilt.52, sa.8, ss.1715-1720, 2012 (SCI-Expanded, Scopus)

215. Thrombotic thrombocytopenic purpura after prophylactic cefuroxime axetil administered in relation to a liposuction procedure.

Eskazan A. E., Salihoglu A., Gulturk E., Ongoren S., Soysal T.
Aesthetic plastic surgery , cilt.36, sa.2, ss.464-7, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

216. Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm

Eskazan A. E., Salihoglu A., Diz-Kucukkaya R., Hancer V. S., Soysal T.
ANNALS OF HEMATOLOGY , cilt.91, sa.2, ss.305-306, 2012 (SCI-Expanded, Scopus)

217. Hypereosinophilic syndrome associated with simultaneous intracardiac thrombi, cerebral thromboembolism and pulmonary embolism.

Buyuktas D., Eskazan A. E., Borekci Ş., Umut S., Ongen Z., Tuzuner N., et al.
Internal medicine (Tokyo, Japan) , cilt.51, sa.3, ss.309-13, 2012 (SCI-Expanded, Scopus) Creative Commons License

218. The association between JAK2V617F mutation and bone marrow fibrosis at diagnosis in patients with philadelphia-negative chronic myeloproliferative neoplasms Philadelphia Negatif Kronik Miyeloproliferatif Neoplazili Hastaların Tanısında JAK2V617F Mutasyonu ile Kemik İliǧindeki Fibrozun İlişkisi

Ar M. C., Buyuktas D., Eskazan A. E., Aydin S. O., Tanrikulu E., Baslar Z., et al.
Turkish Journal of Hematology , cilt.29, sa.3, ss.242-247, 2012 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

219. Essential Thrombocythemia and Multiple Myeloma: Two Rare Diseases in One Patient

Eskazan A. E., Ongoren S., Ar M. C., Soysal T., FERHANOGLU B., Aki H., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.11, sa.5, ss.442-445, 2011 (SCI-Expanded, Scopus)

220. Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients.

Kuru D., Arguden Y. T., Ar M. C., Cirakoglu A., Ongoren S., Yilmaz S., et al.
Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.28, sa.3, ss.186-92, 2011 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

221. Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?

Eskazan A. E., Soysal T., Erbilgin Y., Ozbek U., Ferhanoglu B.
LEUKEMIA RESEARCH , cilt.35, sa.9, 2011 (SCI-Expanded, Scopus)

222. Synchronous detection of hairy cell leukemia and HIV-negative Kaposi's sarcoma of the lymph node: A diagnostic challenge and a rare coincidence

Aydin S. O., Eskazan A. E., Aki H., Ozguroglu M., Baslar Z., Soysal T.
Case Reports in Oncology , cilt.4, sa.3, ss.439-444, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

223. ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method

Erbilgin Y., Catal S., Eskazan A. E., Hatirnaz O., Soysal T., Ozbek U.
TURKISH JOURNAL OF HEMATOLOGY , cilt.28, sa.2, ss.97-102, 2011 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

224. Primary gastrointestinal diffuse large B cell lymphoma presenting with cold agglutinin disease

Eskazan A. E., Akmurad H., Ongoren S., Ozer O., Ferhanoglu B.
Case Reports in Gastroenterology , cilt.5, ss.262-266, 2011 (Scopus) Creative Commons License

225. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.

Eskazan A. E., Soysal T., Ongoren S., Gulturk E., Ferhanoglu B., Aydin Y.
Haematologica , cilt.96, sa.3, 2011 (SCI-Expanded, Scopus)

226. Intracranial mass in a patient with thalassaemia major

Eskazan A. E., Ar M. C., Baslar Z.
British Journal of Haematology , cilt.152, ss.126, 2011 (SCI-Expanded, Scopus)

227. Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: Two case reports

Ozer O., Eskazan A. E., Ar M. C., Beköz H., Tabak F., Ongen G., et al.
Journal of Medical Case Reports , cilt.3, 2009 (Scopus)

228. Cytogenetic clonal evolution in patients with chronic myeloid leukemia

Tarkan-Arguden Y., Ar M. C., Yılmaz Ş., Ongoren S., Kuru D., Ure U., et al.
Biotechnology and Biotechnological Equipment , cilt.23, sa.4, ss.1515-1520, 2009 (SCI-Expanded, Scopus) Creative Commons License

229. Clonal Chromosomal Abnormalities in Philadelphia-Negative Cells and Their Clinical Significance in Patients with Chronic Myeloid Leukemia: Results of a Single Center

Ongoren S., Tarkan-Arguden Y., Ar M. C., Yilmaz S., Ure U., Kuru D., et al.
TURKIYE KLINIKLERI TIP BILIMLERI DERGISI , cilt.29, sa.2, ss.321-330, 2009 (SCI-Expanded, Scopus)

230. Clonal chromosal abnormalities in Philadelphia-negative cells and their clinical significance in patients with chronic myeloid leukemia: Results of a single center

Öngören Ş., ARGÜDEN Y., Ar M. C., Yilmaz Ş., Üre Ü., KURU R. D., et al.
Turkiye Klinikleri Journal of Medical Sciences , cilt.29, sa.2, ss.321-330, 2009 (SCI-Expanded, Scopus)

231. Primary cutaneous immunocytoma/marginal zone B-cell lymphoma: a case with unusual course.

Demirkesen C., Tuzuner N., Su O., Esckazan A. E., Soysal T., Onsun N.
The American Journal of dermatopathology , cilt.26, sa.2, ss.119-22, 2004 (SCI-Expanded, Scopus)
Metrikler

Yayın

261

Yayın (WoS)

235

Yayın (Scopus)

222

Atıf (WoS)

1334

H-İndeks (WoS)

18

Atıf (Scopus)

1347

H-İndeks (Scopus)

19

Atıf (Scholar)

2168

H-İndeks (Scholar)

26

Atıf (TrDizin)

3

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

4

Proje

1

Tez Danışmanlığı

26

Açık Erişim

85
BM Sürdürülebilir Kalkınma Amaçları
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER
SDG 8: AMAÇ 8: İNSANA YAKIŞIR İŞ VE EKONOMİK BÜYÜME
SDG 9: AMAÇ 9: SANAYİ, YENİLİKÇİLİK VE ALTYAPI
SDG 16: AMAÇ 16: BARIŞ VE ADALET
SDG 17: AMAÇ 17: AMAÇLAR İÇİN ORTAKLIKLAR